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Therapeutic Approaches in the Treatment of
Juvenile Dermatomyositis in Patients With Recent-Onset Disease
and in Those Experiencing Disease Flare
An International Multicenter PRINTO Study
Rachana Hasija,1 Angela Pistorio,1 Angelo Ravelli,2 Erkan Demirkaya,1 Raju Khubchandani,3
Dinara Guseinova,1 Clara Malattia,1 Helena Canhao,4 Liora Harel,5 Dirk Foell,6
Carine Wouters,7 Carmen De Cunto,8 Christian Huemer,9 Yukiko Kimura,10 Harald Mangge,11
Carlo Minetti,2 Ellen Berit Nordal,12 Pierre Philippet,13 Rosaria Garozzo,14 Alberto Martini,2
and Nicolino Ruperto,1 for the Pediatric Rheumatology International Trials Organization
Objective. To evaluate response to therapy over a
24-month period in a large prospective international
cohort of patients with juvenile dermatomyositis (DM).
Methods. The study included 145 patients with
recent-onset juvenile DM and 130 juvenile DM patients

experiencing disease flare, all of whom were <18 years
old. Disease activity parameters and therapeutic approaches in 4 geographic areas were analyzed at baseline and at 6, 12, and 24 months. Response was assessed
according to the Pediatric Rheumatology International
Trials Organization (PRINTO) juvenile DM response
criteria, and data were reported “as observed” and in
the intent-to-treat (ITT) population.
Results. Patients with recent-onset juvenile DM at
baseline had higher baseline disease activity and greater
improvement over 24 months when compared to juvenile
DM patients experiencing disease flare at baseline. Methotrexate (MTX) or high-dose corticosteroids were administered more frequently to patients with recent-onset juvenile DM, compared to juvenile DM patients experiencing
disease flare, who were more likely to receive cyclosporine.
Compared to patients from Western and Eastern Europe,
a higher proportion of patients from South and Central
America and North America received pulse steroids, and
the average steroid dosage was higher in the North American and South and Central American patients. The use of
MTX was similar in all 4 regions, while cyclosporin A was
more frequently used in Western Europe. In the “as
observed” analysis, 57.9% of the patients with recent-onset
juvenile DM and 36.4% of the patients experiencing disease flare (P < 0.001) reached at least a 70% response by
PRINTO criteria at 6 months; these proportions had
increased at month 24 to 78.4% and 51.2%, respectively
(P < 0.001). Corresponding results of the ITT analysis
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Gaslini and Università degli Studi di Genova, Genoa, Italy; 3Raju
Khubchandani, MD: Jaslok Hospital and Research Centre, Mumbai,
India; 4Helena Canhao, MD, PhD: University of Lisbon, Lisbon,
Portugal; 5Liora Harel, MD: Schneider Children’s Hospital, Petah
Tikva/Nablus, Israel; 6Dirk Foell, MD: University of Muenster, Muenster, Germany; 7Carine Wouters, MD, PhD: University Hospital
Gasthuisberg, Leuven, Belgium; 8Carmen De Cunto, MD: Hospital
Italiano de Buenos Aires, Buenos Aires, Argentina; 9Christian Huemer, MD: Landeskrankenhaus Bregenz, Bregenz, Austria; 10Yukiko
Kimura, MD: Joseph M. Sanzari Children’s Hospital, Hackensack,
New Jersey; 11Harald Mangge, MD: Medical University of Graz,
Clinical Institute for Medical and Chemical Laboratory Diagnosis,
Graz, Austria; 12Ellen Berit Nordal, MD: University Hospital of
Northern Norway, Tromso, Norway; 13Pierre Philippet, MD: Centre
Hospitalier Chrétien (CHC) Espérance, Montegnee, Belgium; 14Rosaria Garozzo, MD: Azienda Policlinico Università di Catania, Catania, Italy.
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were much lower, with only one-third of the patients able
to maintain the initial assigned therapy over 24 months.
Conclusion. Patients with recent-onset juvenile
DM are more likely to achieve significant clinical improvement over 24 months, when compared to patients
experiencing flares of juvenile DM. Internationally,
various therapeutic approaches are used to treat this
disease.
Juvenile dermatomyositis (DM) is an idiopathic
inflammatory myopathy associated with systemic vasculopathy. Its main characteristics are specific vasculitic
changes in the skin and inflammation of the muscle,
causing progressive muscle weakness. It is the most
common of the juvenile idiopathic inflammatory myopathies, with an annual incidence of 2–4 cases per million
children (1–3). Although a marked improvement in
long-term outcome and survival rate in juvenile DM
patients has been recently documented (4–7), disease
treatment remains largely empirical, and little information is available on standardized evaluation of response
to therapy based on current treatment options.
In 2000, the Pediatric Rheumatology International Trials Organization (PRINTO) (8) started a multinational effort to develop and validate a core set of
outcome variables, known as the PRINTO/American
College of Rheumatology (ACR)/European League
Against Rheumatism (EULAR) juvenile DM core set,
and related response criteria to evaluate response to
therapy in juvenile DM, known as the PRINTO juvenile
DM response criteria (9–11). As part of this international effort, we have also collected standardized information on therapeutic approaches currently being used
for the care of patients with juvenile DM.
The aim of this post hoc analysis was to evaluate
response to therapy over a 24-month period according to
the PRINTO juvenile DM response criteria in a large
international prospective cohort of patients who have
been recently diagnosed as having, or are experiencing
disease flares of, juvenile DM. A secondary aim was to
evaluate current approaches to the treatment of juvenile
DM in 4 geographic areas.
PATIENTS AND METHODS
Study design. Enrollment was started in June 2001,
and ended in March 2004. The participating PRINTO/
Pediatric Rheumatology Collaborative Study Group members
were asked to prospectively collect data on clinical, laboratory,
and therapeutic modalities in all patients seen consecutively in
their units who had the following features: 1) probable or
definite juvenile DM as defined by disease criteria (12,13), 2)
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age younger than 18 years, and 3) disease in an active phase,
defined as either the need to start corticosteroid therapy
and/or a new immunosuppressive medication or to receive a
major increase in the dosage of ongoing corticosteroid and/or
other immunosuppressive medications. Patients were excluded
from the study if, at baseline, their DM was in drug-induced or
spontaneous clinical remission, they were receiving stable
therapy, or they had a concomitant serious illness. Data were
collected at baseline and at 6, 12, and 24 months. For the
purposes of this analysis, we included patients who had at least
baseline and 6-month data available. In order to take into
account the possible differences in the therapeutic approaches
and clinical outcome, patients were grouped into 2 different
categories, based on whether they had been recently diagnosed
and were previously untreated, or if they had longer disease
duration and were experiencing a flare and/or requiring an
escalation of therapy. Patients were also divided according to 4
geographic areas: Western Europe and Eastern Europe, and
South and Central America and North America. In each
center, written or verbal informed consent was obtained from
a parent or legal guardian, according to the requirements of
the local ethics committees.
PRINTO/ACR/EULAR juvenile DM core set measures. The following 6 PRINTO juvenile DM core set measures (10) were assessed at each time point: 1) physician’s
global assessment of the patient’s overall disease activity, using
a 10-cm visual analog scale (VAS) (14); 2) muscle strength,
using the Childhood Myositis Assessment Scale (CMAS) (15–
17); 3) global disease activity assessment, using the Disease
Activity Score (DAS) for juvenile DM (18); 4) functional
ability, using the Childhood Health Assessment Questionnaire
(C-HAQ) (19–22); 5) parent’s global assessment of the patient’s overall well-being, using a 10-cm VAS (14,19,20); and 6)
health-related quality of life, using the physical summary score
of the Child Health Questionnaire (CHQ), parent version
(20,23). Scoring and content of all the instruments have been
described previously (10).
Treatment history. At each time point, we collected
information on the dosage of corticosteroids, methotrexate
(MTX), cyclosporin A (CSA), azathioprine (AZA), intravenous immunoglobulin (IVIG), and any other medications
used. In addition, as per the inclusion criteria of the main
study, data were collected to document any therapy the patient
received before the first visit and to note all medications that
had recently been introduced or had an important change in
dosage.
Evaluation of response to therapy. According to the
provisional PRINTO definition of improvement in juvenile
DM (11), patients were considered to be improved if they
demonstrated ⱖ20% improvement from baseline in any 3 of
the 6 core set measures (10), with no more than 1 of the
remaining measures, which could not be muscle strength
worsening by ⬎30% (PRINTO juvenile DM 20). We also
evaluated patients by more stringent definitions of improvement, requiring 50%, 70%, and 90% improvement (PRINTO
juvenile DM 50, 70, and 90, respectively). For the purposes of
this analysis, disease was provisionally defined as clinically
inactive if muscle strength was normal (CMAS ⱖ48), physician
global assessment of disease activity was ⱕ0.5 cm on a 10-cm
VAS, and levels of creatine kinase were normal (ⱕ150 units/
liter) while the patient was receiving medication.
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Responder data were reported “as observed” and in
the intent-to-treat (ITT) population. In the “as observed”
analysis, responder status was reported with regard to whatever specific treatment the patient was receiving at the time of
the assessment. In the ITT analysis, baseline medications (e.g.,
steroids alone, steroids plus MTX, steroids plus CSA, etc.)
were considered the assigned treatment; if at the followup visit
the patient had received a change in therapy (e.g., addition of
drugs different from those used at baseline), then the patient
was considered a nonresponder to the baseline-assigned treatment for the remaining followup, irrespective of the observed
responder status. The hypothesis guiding the ITT analysis was
that initial therapeutic choices, based upon the decision of the
physician or family, cannot be followed linearly for the entire
course of a chronic condition like juvenile DM, and therefore
therapeutic modifications, in either dosing, add-on therapy, or
drug switching, are necessary to properly control the disease.
For the purposes of this report, disease flare has been defined
according to the physician’s decision to increase, modify, or
add corticosteroid therapy and/or a new immunosuppressive
agent, as per the inclusion criteria.
Statistical analysis. Data were reported as medians
(interquartile range [IQR]) or as absolute numbers and percentages. Quantitative data were analyzed by Kruskal-Wallis
nonparametric test, followed by Dunn’s test. All comparisons
at followup were made using nonparametric analysis of variance (Friedman’s test for repeated measurements); post hoc
comparisons were made by Wilcoxon’s matched pairs test with
P values corrected by Bonferroni adjustment (Pcorr). Categorical data were compared among groups of patients (4 geographic areas) by chi-square test or Fisher’s exact test with
Bonferroni correction for multiple comparisons. Data were
entered in an Access XP database and analyzed with Excel XP
(Microsoft), XLSTAT 6.1.9 (Addinsoft), Statistica 6.0 (StatSoft), and Stata 7.0 (Stata Corporation) by 2 of the authors
(AP and NR).

RESULTS
Demographic characteristics. A total of 294 patients were enrolled from 97 centers in 36 countries as
follows: Argentina (n ⫽ 35), Australia (n ⫽ 2), Austria
(n ⫽ 2), Belgium (n ⫽ 3), Brazil (n ⫽ 28), Bulgaria (n ⫽
3), Canada (n ⫽ 3), Chile (n ⫽ 3), Costa Rica (n ⫽ 7),
Croatia (n ⫽ 5), Cuba (n ⫽ 1), Czech Republic (n ⫽ 5),
Denmark (n ⫽ 3), Finland (n ⫽ 2), France (n ⫽ 11),
Germany (n ⫽ 20), Greece (n ⫽ 6), Hungary (n ⫽ 1),
Israel (n ⫽ 4), Italy (n ⫽ 33), Latvia (n ⫽ 3), Mexico
(n ⫽ 3), Netherlands (n ⫽ 17), Norway (n ⫽ 5), Poland
(n ⫽ 4), Portugal (n ⫽ 6), Serbia and Montenegro (n ⫽
6), Singapore (n ⫽ 1), Slovakia (n ⫽ 3), Slovenia (n ⫽ 1),
Spain (n ⫽ 10), Sweden (n ⫽ 2), Switzerland (n ⫽ 11),
Turkey (n ⫽ 6), the UK (n ⫽ 24), and the US (n ⫽ 15).
The investigators at each center are listed in Appendix
A. Of the 294 patients enrolled, 19 were excluded from
the study (9 patients were excluded for polymyositis
without cutaneous manifestations, 1 patient was later

diagnosed as having muscular dystrophy, and 9 patients
were lost to followup soon after the baseline visit).
Of the remaining 275 patients included in the
analysis (94%) who had data available for at least
baseline and 6-month assessments, 168 patients were
female (61%) and 107 were male (39%); the median age
at disease onset was 7.2 years (IQR 4.3–10.2 years), and
median disease duration at baseline was 7.7 months
(IQR 2.7–25.3 months) in the entire group, 3.0 months
(IQR 1.6–5.6 months) in patients with recent-onset
juvenile DM (n ⫽ 145), and 27.3 months (IQR 12.7–49.2
months) in those experiencing disease flare later in the
course of juvenile DM (n ⫽ 130). Seventy-seven patients
(28%) were lost to followup at 12 months and 10
additional patients (4%) were lost to followup at 24
months. A total of 174 patients (63%) had all 4 assessments available; there were no differences in sex distribution, age at onset, disease duration, age at first visit, or
other baseline characteristics between the 174 patients
with all 4 assessments available and the remaining 101
patients lost to followup after month 6 (data not shown).
Table 1 shows the median changes over time,
from baseline to month 24, in the PRINTO juvenile DM
core set variables in the 2 groups of patients (those with
a recent diagnosis versus those experiencing disease
flare). At baseline, patients experiencing disease flare
had statistically significantly less severe muscle involvement, less disease activity, less disability, and better
scores on the parental global assessment of the patient’s
overall well-being, when compared to patients with
recent-onset juvenile DM. There were no statistically
significant differences between the 2 groups in terms of
the physician’s global evaluation of the patient’s overall
disease activity and health-related quality of life as
assessed with the CHQ.
In both groups of patients, all measures showed a
statistically significant change over time (P ⬍ 0.0001). In
comparison to baseline values, improvement was most
pronounced during the initial 6 months and continued
up to month 12; additionally, improvement was more
pronounced in the patients with recent-onset juvenile
DM than in the patients experiencing disease flare. In
the subsequent 12 months of followup, measures remained substantially unchanged, with a trend toward a
statistically significantly lower level of improvement for
patients experiencing disease flare. In particular, the
physician’s global assessment of disease activity changed
from a median baseline value of 5.7 to 0.0 by month 24
in patients with recent-onset disease, as compared to a
change from 5.2 to 0.5 in the patients experiencing
disease flare. Muscle strength, as measured by the
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Table 1. Descriptive characteristics of the PRINTO/ACR/EULAR core set variables for the 275 patients included in the analysis*
Variable
Physician’s global assessment of the
patient’s overall disease activity
(0–10 cm VAS)
Patients with recent-onset disease
Patients experiencing disease flare
CMAS (0–52 score)
Patients with recent-onset disease
Patients experiencing disease flare
DAS (0–20 score)
Patients with recent-onset disease
Patients experiencing disease flare
C-HAQ (0–3 score)
Patients with recent-onset disease
Patients experiencing disease flare
Parent’s global assessment of the overall
patient’s well-being (0–10-cm VAS)
Patients with recent-onset disease
Patients experiencing disease flare
Physical summary score on Child Health
Questionnaire (40–60 score)
Patients with recent-onset disease
Patients experiencing disease flare

Month 0
(n ⫽ 275)

Month 6
(n ⫽ 275)

Month 12
(n ⫽ 198)

Month 24
(n ⫽ 188)

P†

5.7 (3.9–7.2)
5.2 (3.1–6.9)

0.7 (0.2–1.9)‡
1.2 (0.4–3.2)‡

0.2 (0–0.9)‡
0.8 (0–2.2)

0 (0–1)
0.5 (0–2)§

⬍0.0001
⬍0.0001

22 (12–33)
30 (15–40)§

47 (40–50)‡
45 (35–49)‡

49 (44–52)‡
47 (40–51)

51 (45–52)¶
49 (40–52)

⬍0.0001
⬍0.0001

13 (11–15)
12 (9–14)‡

4 (3–6)‡
6 (3–9)‡

3 (0–6)Ⲇ
5 (3–8)§

2 (0–5)
4 (1–8)§

⬍0.0001
⬍0.0001

0.25 (0–0.83)‡
0.5 (0–1.14)‡

0 (0–0.25)‡
0.13 (0–0.88)§

0 (0–0.13)
0.25 (0–1.38)§

⬍0.0001
⬍0.0001

0.5 (0–1.8)
0.4 (0–3)

0.2 (0–0.9)¶
0.2 (0–2.9)

⬍0.0001
⬍0.0001

2 (1.38–2.63)
1.38 (0.75–2.38)§
6.3 (3.9–7.8)
4.9 (2–6.7)§

0.8 (0–1.9)‡
1.0 (0.2–3.2)‡

29.3 (23.3–38.6)
34.1 (23.9–45.0)

52.2 (42.5–54.7)‡
47.7 (39.7–53.5)‡

53.5 (48.2–55.3)¶
52.2 (42.9–54)

53.1 (49.3–54.9)
50.8 (41.2–53.2)§

⬍0.0001
⬍0.0001

* Values are the median (interquartile range). A higher score for the physician’s global assessment of patient’s overall disease activity, the Disease
Activity Score (DAS), the Childhood Health Assessment Questionnaire (C-HAQ), and the parent’s global assessment of patient well-being denotes
worse disease activity; a lower score for the Childhood Myositis Assessment Scale (CMAS) and physical summary score on Child Health
Questionnaire denotes worse disease activity. PRINTO/ACR/EULAR ⫽ Pediatric Rheumatology International Trials Organization/American
College of Rheumatology/European League Against Rheumatism; VAS ⫽ visual analog scale.
† Significance of the change from baseline to month 24, by repeated-measures nonparametric analysis of variance.
‡ Corrected P (Pcorr) ⬍ 0.001 versus previous assessment.
§ P ⬍ 0.05 versus patients with recent-onset disease.
¶ Pcorr ⬍ 0.05 versus previous assessment.
Ⲇ Pcorr ⬍ 0.01 versus previous assessment.

CMAS, reached values close to normal (median score
46) by month 6 in both groups and remained constant
thereafter. Similarly, the DAS showed a statistically
significant change in the initial 6 months that was
maintained in the following 18 months in both groups.
These observations were substantially confirmed
by the change in the parent’s reported outcomes, such as
the parent’s global assessment of overall well-being and
pain and the C-HAQ, but some degree of physical
disability remained at month 24 in those patients who
had been experiencing disease flare at baseline (median
C-HAQ 0.25 versus 0.0 in patients experiencing disease
flare versus patients with recent-onset disease). Notably,
the physical summary score of the CHQ at baseline was
2 SD below that of the healthy controls in the patients
with recent-onset juvenile DM and 1 SD below that of
healthy controls in the patients experiencing disease
flare, and both groups reached normal levels of physical
well-being by month 6, which was maintained thereafter.
Therapeutic approaches over time. Table 2 shows
the therapeutic approaches over time in both groups of

patients. With regard to treatment at baseline, almost all
patients (269 of 275; 98%) were receiving corticosteroids, with 192 (70%) having recently begun taking
intravenous pulse or oral steroids, and 91 (33%) being
treated with steroids in combination with MTX. The
frequency of patients newly starting any corticosteroids
or MTX was higher in the group of patients with
recent-onset juvenile DM compared to the group experiencing disease flare (corticosteroid use in 90.3% versus
46.9%; MTX in 89.3% versus 52.6%). The same trend
was observed in patients treated with pulse corticosteroids. Conversely, CSA was used less frequently in
patients with recent-onset juvenile DM compared to
patients experiencing disease flare (5.5% versus 27.7%).
When IVIG treatment was assessed, there was no statistically significant difference between the 2 groups.
The median dosage of prednisone equivalent at
baseline was 1.31 mg/kg/day (IQR 0.78–1.94) in the
group of patients with recent-onset disease and 0.75
mg/kg/day (IQR 0.38–1.25) in the group experiencing
disease flare; prednisone dosages were decreased over
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Table 2. Treatment modalities used at various time points during the study period*

Patients receiving any steroids
Patients with recent-onset disease
Patients experiencing disease flare
Patients starting steroids
Patients with recent-onset disease
Patients experiencing disease flare
Patients receiving pulse steroids
Patients with recent-onset disease
Patients experiencing disease flare
Dosage of prednisone equivalent,
median (interquartile range) mg/kg/day
Patients with recent-onset disease
Patients experiencing disease flare
Patients receiving MTX
Patients with recent-onset disease
Patients experiencing disease flare
Patients starting MTX
Patients with recent-onset disease
Patients experiencing disease flare
Patients receiving cyclosporin A
Patients with recent-onset disease
Patients experiencing disease flare
Patients receiving IVIG
Patients with recent-onset disease
Patients experiencing disease flare
Patients not receiving any treatment
Patients with recent-onset disease
Patients experiencing disease flare

Month 0
(n ⫽ 275)

Month 6
(n ⫽ 275)

Month 12
(n ⫽ 198)

Month 24
(n ⫽ 188)

P†

142/145 (97.9)
127/130 (97.7)

139/145 (95.9)
117/130 (90.0)§

70/103 (68.0)‡
75/95 (78.9)

41/98 (41.8)‡
56/90 (62.2)§¶

⬍0.0001
⬍0.0001

131/145 (90.3)
61/130 (46.9)¶

2/145 (1.4)‡
2/130 (1.5)‡

0/103 (0.0)
3/95 (3.2)

2/98 (2.0)
3/90 (3.3)

⬍0.0001
⬍0.0001

64/145 (44.1)
36/130 (27.7)¶

21/145 (14.5)‡
14/130 (10.8)Ⲇ

8/103 (7.8)
7/95 (7.4)

2/98 (2.0)
6/90 (6.7)

⬍0.0001
⬍0.0001

1.31 (0.78–1.94)
(n ⫽ 138)
0.75 (0.38–1.25)
(n ⫽ 123)¶

0.34 (0.19–0.62)‡
(n ⫽ 139)
0.29 (0.15–0.55)
(n ⫽ 116)‡¶

56/145 (38.6)
78/130 (60)¶

85/145 (58.6)Ⲇ
79/130 (60.8)

50/56 (89.3)
41/78 (52.6)¶

32/85 (37.6)‡
8/79 (10.1)‡¶

⬍0.0001

0.23 (0.13–0.41)
(n ⫽ 68)‡
0.18 (0.10–0.35)
(n ⫽ 73)Ⲇ

0.27 (0.13–0.40)
(n ⫽ 41)
0.16 (0.08–0.32)
(n ⫽ 54)§

66/103 (64.1)
55/95 (57.9)

58/98 (59.2)
56/90 (62.2)

0.0001
0.94

7/58 (12.1)
10/56 (17.9)

⬍0.0001
⬍0.0001

12/66 (18.2)§
8/55 (14.5)

⬍0.0001

8/145 (5.5)
36/130 (27.7)¶

19/145 (13.1)
34/130 (26.2)¶

12/103 (11.7)
19/95 (20.0)

15/98 (15.3)
18/90 (20.0)

0.07
0.40

21/145 (14.5)
17/130 (13.1)

16/145 (11.0)
13/130 (10.0)

4/103 (3.9)§
6/95 (6.3)

3/98 (3.1)
6/90 (6.7)

0.003
0.27

–
–

3/145 (2.1)
2/130 (1.5)

10/103 (9.7)§
11/95 (11.6)Ⲇ

26/98 (26.5)Ⲇ
13/90 (14.4)¶

⬍0.0001
0.001

* Except where indicated otherwise, values are the number of patients receiving treatment/number of patients in group (%). MTX ⫽ methotrexate;
IVIG ⫽ intravenous immunoglobulin.
† Significance of the change from baseline to month 24, by repeated-measures nonparametric analysis of variance.
‡ Corrected P (Pcorr) ⬍ 0.001 versus previous assessment.
§ Pcorr ⬍ 0.05 versus previous assessment.
¶ P ⬍ 0.05 versus patients with recent-onset disease.
Ⲇ Pcorr ⬍ 0.01 versus previous assessment.

the course of the study in both groups (especially in the
initial 6 months), and remained unchanged thereafter.
Pulse steroids were used more frequently at baseline and
at 6 months (particularly in the group of patients with
recent-onset disease), and to a lesser extent in the
following months. At 6 months, ⬎90% of the patients
were receving corticosteroids; this had decreased to 73%
of all patients at 12 months. At 24 months, patients with
recent-onset juvenile DM were less likely to be receiving
corticosteroids, compared to patients experiencing disease flare at study baseline (41.8% versus 62.2%). The
median dosage of MTX at baseline was 14 mg/m2/week,
and changed little over time in both groups. Five of the
275 patients assessed at 6 months (1.8%), 21 of 198
patients assessed at 12 months (10.6%), and 39 of 188
patients assessed at 24 months (21.3%) were not being
treated with any medication, with patients who had recent-

onset juvenile DM having discontinued therapy by 24
months at a higher rate than those experiencing disease
flare (26.5% versus 14.4%; Pcorr ⬍ 0.05).
The observed therapeutic approaches at baseline
for the 4 main geographic areas (Western and Eastern
Europe and South and Central and North America) are
reported in Table 3. Most patients were from Western
Europe (56%) and South and Central America (25%),
which are the classic catchment areas for PRINTO.
At baseline, in each geographic area, patients
with recent-onset juvenile DM were significantly more
likely to begin treatment with corticosteroids than patients experiencing disease flare, with the exception of
patients from North America, for whom the sample was
too small to calculate significance. Similarly, patients
with recent-onset disease were more likely to receive
pulse steroids when compared with patients experienc-
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Table 3. Treatment approaches at baseline in the 4 main geographic areas*
Western Europe
(n ⫽ 154; 56%)
Patients receiving any steroids
Patients with recent-onset disease
Patients experiencing disease flare
Patients starting steroids
Patients with recent-onset disease
Patients experiencing disease flare
Patients receiving pulse steroids
Patients with recent-onset disease
Patients experiencing disease flare
Dosage of prednisone equivalent,
median (interquartile range) mg/kg/day
Patients with recent-onset disease
Patients experiencing disease flare
Patients receiving MTX
Patients with recent-onset disease
Patients experiencing disease flare
Patients starting MTX
Patients with recent-onset disease
Patients experiencing disease flare
Patients receiving cyclosporin A
Patients with recent-onset disease
Patients experiencing disease flare
Patients receiving IVIG
Patients with recent-onset disease
Patients experiencing disease flare

Eastern Europe
(n ⫽ 32; 12%)

South and Central America
(n ⫽ 68; 25%)

North America
(n ⫽ 21; 8%)

P†

79/81 (97.5)
71/73 (97.3)

16/16 (100)
16/16 (100)

34/34 (100)
33/34 (97.1)

13/14 (92.9)
7/7 (100)

0.41‡
0.69‡

70/81 (86.4)
31/73 (42.5)§

14/16 (87.5)
6/16 (37.5)§

34/34 (100)
19/34 (55.9)§

13/14 (92.9)
5/7 (71.4)

0.08‡
0.29‡

31/81 (38.3)
20/73 (27.4)

3/16 (18.8)
3/16 (18.8)

20/34 (58.8)¶
11/34 (32.4)§

10/14 (71.4)
2/7 (28.6)

0.006Ⲇ
0.84‡

1.27 (0.93–1.94)
0.52 (0.33–0.94)§

1.11 (0.59–1.89)
0.82 (0.53–1.20)

1.69 (1.21–2.02)
1.12 (0.56–1.95)§

32/81 (39.5)
42/73 (57.5)§

6/16 (37.5)
12/16 (75.0)§

10/34 (29.4)
18/34 (52.9)§

8/14 (57.1)
6/7 (85.7)

0.35Ⲇ
0.25‡

29/32 (90.6)
18/42 (42.9)§

6/6 (100)
8/12 (66.7)

8/10 (80.0)
12/18 (66.7)

7/8 (87.5)
3/6 (50.0)

0.71‡
0.26‡

6/81 (7.4)
29/73 (39.7)§

2/16 (12.5)
3/16 (18.8)

0/34 (0)
4/34 (11.8)§

0/14 (0)
0/7 (0)

0.18‡
0.004‡

8/81 (9.9)
12/73 (16.4)

3/16 (18.8)
4/16 (25.0)

7/34 (20.6)
1/34 (2.9)

3/14 (21.4)
0/7 (0)

0.27‡
0.07‡

1.08 (0.59–1.51)¶ 0.041**
1.25 (1.04–1.57) 0.0009**

* Except where indicated otherwise, values are the number of patients receiving treatment/number of patients in group (%). All P values were
adjusted by Bonferroni method (Pcorr). MTX methotrexate; IVIG ⫽ intravenous immunoglobulin.
† Significance of the difference among all 4 groups.
‡ By Fisher’s exact test.
§ Significant difference in comparison to patients with recent-onset disease.
¶ Pcorr ⬍ 0.05 versus patients experiencing disease flares.
Ⲇ By chi-square test.
** By Kruskal-Wallis test.

ing disease flare, especially if they were in North America (71.4% versus 28.6% in patients experiencing disease
flare) and South and Central America (58.8% versus
32.4%; Pcorr ⬍ 0.05). Overall, the median prednisone
equivalent dosage was significantly higher in patients
with recent-onset juvenile DM (median between 1.08
mg/kg/day and 1.69 mg/kg/day in the 4 geographic
groups) as compared to daily prednisone dosage in
patients experiencing disease flare (median between
0.52 mg/kg/day and 1.25 mg/kg/day in the 4 geographic
groups). South American patients with recent-onset
juvenile DM tended to receive a higher baseline dosage
of corticosteroids, with a median of 1.69 mg/kg/day,
as compared to a range of 1.08–1.27 mg/kg/day in the
other geographic areas. The starting prednisone equivalent dosages for patients experiencing disease flare
were higher for South and Central America and North
America (median 1.12 mg/kg/day and 1.25 mg/kg/day,
respectively) in comparison to both Western and East-

ern European locations (median 0.52 mg/kg/day and
0.82 mg/kg/day, respectively).
The use of MTX at baseline was similar in all 4
regions for both groups of patients, with no statistically
significant differences (although North American patients were treated with it the most); patients experiencing disease flare were more likely to receive MTX as
compared to patients with recent-onset disease. CSA
was more frequently used in Western Europe, especially
in patients experiencing disease flare, and it was not
used at all in North America. The proportion of patients
with recent-onset juvenile DM receiving IVIG was highest in North and South and Central America, while the
proportion of patients experiencing disease flare who
received IVIG was highest in Western and Eastern
Europe.
Response to therapy according to the PRINTO
juvenile DM response criteria. The PRINTO 20, 50, 70,
and 90 juvenile DM response criteria for improvement
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significant differences were observed at months 12 and
24; patients with recent-onset juvenile DM were more
likely to respond or to reach a status of inactive disease.
The greatest level of improvement was reached in the
initial 6 months, and was maintained or improved upon
thereafter. When more stringent response criteria of
improvement were considered, we found that a
PRINTO juvenile DM 70 level of response was reached
at 6 months by 57.9% of patients with recent-onset
juvenile DM compared to 36.4% of the patients experiencing juvenile DM flares (P ⬍ 0.001), with steady
increases over time to 78.4% and 51.2% (P ⬍ 0.001),

Figure 1. Pediatric Rheumatology International Trials Organization
juvenile dermatomyositis (JDM) 20%, 50%, 70%, and 90% improvement (PRINTO juvenile DM 20, 50, 70, and 90, respectively) and
clinically inactive disease status over time in the “as observed” analysis.
A, Responder status in the group of patients with recent-onset juvenile
DM. B, Corresponding results in the group of patients who experienced disease flare later in the course of juvenile DM. P values are
versus the group with recent-onset juvenile DM, at the corresponding
time point.

and the number of patients considered to have inactive
disease while receiving medication in the “as observed”
analysis are reported in Figures 1A and B. At the
6-month assessment, the PRINTO 20, 50, 70, and 90
levels of response were significantly higher in patients
with recent-onset juvenile DM when compared with the
group of patients experiencing disease flare (e.g.,
PRINTO 50 response criteria were met in 80% of
patients versus 55.8%, respectively; P ⬍ 0.001). Similar

Figure 2. PRINTO juvenile DM 20, 50, 70, and 90 and clinically
inactive disease status over time in the intent-to-treat analysis. A,
Responder status in the group of patients with recent-onset juvenile
DM. B, Corresponding results in the group of patients who experienced disease flare later in the course of the disease. P value is versus
the group with recent-onset juvenile DM, at the corresponding time
point. See Figure 1 for definitions.
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respectively, by 24 months. The same trend was observed
in analyses of the most stringent level of improvement,
with an inactive disease status reached at 24 months by
41.8% of patients with recent-onset disease and by
23.3% of those experiencing disease flare.
The corresponding levels of improvement were
lower in the ITT population when compared to the “as
observed” analysis (Figures 2A and B). Additionally, in
the ITT population, there were no significant differences
at any time point between the patients with recent-onset
juvenile DM and those experiencing disease flare. By
24 months, a PRINTO 90 level of response had been
reached by 32.8% of patients with recent-onset disease
and 34% of those experiencing disease flare, with a
nonsignificant trend toward more responders in the
subgroup of patients with disease flare. Further investigation revealed that results were comparable when all
analyses were repeated in the 174 of 275 patients (63%)
who had all 4 assessments available (data not shown).
DISCUSSION
In this large international prospective cohort of
patients with juvenile DM, treatment, as agreed upon by
the physician and family, resulted in substantial response
in the initial 6 months. The response increased or was
maintained over time and was significantly higher in
patients with recent-onset juvenile DM as compared to
patients with juvenile DM who experienced disease flare
during the course of disease.
A multinational effort was set up by PRINTO
and other organizations in order to develop and validate
a core set of outcome variables and a definition of
clinical improvement for evaluating response to therapy
in inflammatory myopathies of adults and children (9–
11,24–27). One of the objectives was to investigate
treatment results using standardized and comparable
measures. As assessed by the PRINTO juvenile DM
core set, the children in this cohort showed the greatest
improvement in the initial 6 months of treatment. The
improvement in the individual PRINTO juvenile DM
core set parameters was maintained through the following 18 months, resulting in levels that were close to
normal for most of the variables assessed. These results
were essentially similar in the 2 groups of juvenile DM
patients examined (those with recent-onset disease and
those experiencing disease flare), although there was a
trend toward greater improvement over time in the first
group. The higher level of disease activity observed in
the patients with recent-onset juvenile DM at baseline
may partially explain the greater improvement observed
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over time, when compared with the patients who were
experiencing disease flare at baseline. Similar to findings
in the current study, Seshadri et al (28) reported that
there was little difference in efficacy outcome in patients
treated at baseline with aggressive therapy (pulse steroids or oral steroids 5–30 mg/kg/day) when compared to
patients receiving standard therapy (steroids 1–2 mg/kg/
day).
Treatment of juvenile DM, like treatment of DM,
is largely empirical, since, to date, no randomized trials
have been conducted. After the introduction of corticosteroid therapy in the 1970s, mortality was greatly reduced (3), with a concurrent marked improvement in
functional outcomes (4). In order to limit or prevent the
well-known corticosteroid toxicity in children who are
still growing, and to prevent the occurrence of subsequent disease flares, it has become standard practice to
administer corticosteroids either orally or as pulse therapy (29), as well as to combine corticosteroids with other
treatment such as MTX (30–33), CSA (34–36), IVIG
(37–41), and other medications, as corticosteroidsparing agents.
The study presented herein demonstrates that
corticosteroids remain the most important treatment in
controlling disease at onset. Corticosteroids were administered orally, with a relatively high median dosage (1.31
mg/kg/day), in almost all patients with recent-onset
disease, with ⬎40% of patients receiving additional
pulse corticosteroids. In contrast, patients who had had
longer disease duration and were treated for a disease
flare tended to receive lower baseline corticosteroid
dosages, and were more likely to receive steroid-sparing
therapies, such as MTX or CSA. Corticosteroid dosages
were steadily decreased during the initial 6 months and
were maintained after that time point at lower dosages
in both of the groups examined, but patients with
recent-onset juvenile DM were more likely to completely discontinue treatment with corticosteroids. Combination therapy with other immunosuppressive medication at baseline (particularly MTX) was commonly used
in all 4 geographic regions and increased steadily in the
subsequent months of treatment as a steroid-sparing
agent or to prevent flares, with ⬃60% of children having
received a course of MTX over a 2-year span. Other
medications, such CSA, were more frequently used in
patients experiencing juvenile DM flare who had longer
disease duration, while IVIG was used less frequently in
these patients, perhaps reflecting the low availability and
high cost of this treatment modality.
When baseline was analyzed in the 4 main geographic PRINTO catchment areas, there were differ-
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ences in the initial therapeutic approach for patients
with recent-onset juvenile DM, with pulse corticosteroids being prescribed most frequently in North and
South and Central America, followed by Western Europe; CSA appeared to be more frequently prescribed in
Western and Eastern Europe for both patients with
recent-onset disease and those experiencing disease
flare. South and Central American physicians tended
to prescribe higher initial dosages of corticosteroids,
especially in patients with recent-onset disease. MTX
was uniformly used in all 4 geographic areas, in higher
proportions in patients experiencing disease flare than in
patients with recent-onset disease. Our observations are
consistent with those of Stringer et al (42), who reported
that, among the majority of North American pediatric
rheumatologists, corticosteroids and MTX appear to be
the standard initial treatment approach for typical cases
of juvenile DM, with variability in the route of administration.
The lack of randomized trials and internationally
agreed-upon guidelines for treatment of juvenile DM
may explain differences that are based on personal
practice and experience, local attitudes, and drug availability. Despite these differences in therapeutic approaches, children in our study showed improvement
over time regardless of which therapy was used. The
main trend in treatment is to use corticosteroids initially,
followed by a careful tapering of corticosteroids and
then introduce a second-line agent, such as MTX.
To the best of our knowledge, this is the first
report on response to therapy as determined by standardized response criteria for evaluating improvement.
The analysis of response to therapy according to the
PRINTO juvenile DM response criteria was performed
in 2 ways. In the “as observed” analysis, patients were
classified as responders based on their status on the day
of the assessment, and independent of changes in treatment that may have occurred. By this method, the
response rate according to the PRINTO juvenile DM 20
response criteria (or the more stringent 50, 70, and 90
response criteria) appeared to be satisfactory over time,
with 64.9% of the group of patients who had recentonset disease exhibiting at least a 90% improvement
after 2 years of treatment. In patients who were experiencing disease flare at baseline, the corresponding level
of improvement was significantly lower, indicating that
in this group of patients, whose disease relapsed over
time, disease control was more difficult to achieve. This
observation indicates that therapeutic response is less
likely to occur when a patient experiences relapse later
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in the course of the disease as compared to the untreated patients with recent-onset disease.
In the ITT analysis, patients were assessed based
on the initial treatment chosen by the local physician,
and any subsequent major deviation (e.g. add-on therapy, switch to alternative medication, or major increase
in dosage, especially in corticosteroids) resulted in a
classification of the patient’s disease as nonresponsive.
When planning for the ITT analysis was begun,
our hypothesis was that the initial treatment, thought to
be the best choice for each patient, cannot be linearly
followed in a chronic condition like juvenile DM, and
that deviations from the initial treatment are necessary
and would result in lower corresponding levels of response than with the “as observed” analysis. Our results
in fact confirmed that levels of improvement in the ITT
analysis were lower than in the “as observed” analysis
both among patients with recent-onset disease and
among those experiencing disease flare. In addition,
when the 2 groups of patients were assessed in the ITT
analysis, there appeared to be no significant difference
in the level of response to treatment. The initial assigned
treatment could be maintained in only approximately
one-third of patients with recent-onset juvenile DM and
a slightly greater proportion of the patients experiencing
disease flare.
The discrepancy observed in the results of our
“as-observed” and ITT analyses emphasizes the wellknown differences between daily clinical practice, in
which treatment modalities are more liberal and are
modified according to physician interpretation of current patient status, and clinical trials, in which the
assigned treatment is the cornerstone of the analysis and
any deviation must be counted in the responder status.
Our results are consistent with those of Pincus et al, who
argued that only 30% of the rheumatoid arthritis population seen in clinical practice would be eligible for
inclusion in a clinical trial, and therefore that the results
of the clinical trials, while of utmost importance, cannot
automatically be translated to similar levels of response
in the treatment of chronic rheumatic conditions in
clinical practice (43,44).
A limitation of our study is that the treatment was
assigned based on physician decision, and the study was
not designed or conducted as a randomized clinical trial.
However, the large number of patients from many
countries, and our use of standardized assessment methods to evaluate response to therapy, is the main strength
of this prospective study.
In conclusion, in the context of current clinical
practices for the treatment of juvenile DM, patients with
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recent-onset disease were more likely to exhibit significant clinical improvement (up to 90%), when compared
to patients experiencing disease flare, over a 24-month
period. In the 4 geographic areas analyzed, several
differences in the initial therapeutic approaches were
noted.
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